Breast Surgery Fellowship Now Offered at Meridian Cancer Care As the only system partner of Rutgers Cancer Insti- tute of New Jersey, Meridian Cancer Care, part of Hack- ensack Meridian Health, is now collaborating with the institute in its first fellowship program to provide boardeligible surgeons an opportunity to learn about a variety of breast cancer treatments and practices. The Breast Surgery Fellowship Program, in collaboration with Rutgers cancer institute and Rutgers Robert Wood Johnson medical School, begins with a one-month rotation at Jersey Shore University Medical Center and includes one year of clinical studies at Rutgers Robert Wood Johnson medical School and other affiliated hospitals. year one of the rotation will allow for the comprehensive learning and experience of a multidisciplinary approach to diagnosing, treating and rehabilitating breast cancer patients. The fellow will work with a variety of breast care specialists including medical, radiation and surgical oncologists and will have the opportunity to learn from and work alongside these experts in pre-and postoperative cases in multiple clinics. Participants also will be exposed to advanced techniques and approaches from working with breast cancer specialists from meridian cancer care. “it’s a 360-degree learning experience where fellows will receive quality experience from meridian’s cancer care team and, in turn, the team can acquire and implement new techniques of treatment and diagnosis,” says Denise Johnson Miller, MD, FACS, medical director of breast surgery at meridian cancer care. Plans are being explored to add a second breast fellow in 2018. I DeB B i e VOGeL Denise Johnson Miller, MD, FACS, (right) medical director of breast surgery at Meridian Cancer Care and breast surgical fellow Maria Ham Kowzun, MD. Kudos! Krasna, MD, medical director of Meridian Cancer Care, part of Hackensack Meridian Health, who received a $1.9 million grant from the National Cancer Institute and Leidos Biomedical Research. The funding will support Dr. Krasna’s work with The Clinical Proteomic Tumor Analysis Consortium, sponsored C ongratulations to Mark by the Office of Cancer Clinical Proteomics Research and The Frederick National Laboratory for Cancer Research, which is dedicated to the understanding of cancer biology. Samples will be collected to conduct proteogenomic analyses on certain cancer types. The purpose of this integrative approach is to provide the broad scientific community with knowledge that links genotype to proteotype and, ultimately, phenotype. I Autumn 2016 I Cancer Connection I 31